A meta-analysis of 34 trials and over 50,000 patients found no increased cancer risk with GLP-1 receptor agonists, including liraglutide, exenatide, and semaglutide.
OR 1.04 (no increase)Across 50,452 patients in 34 randomized trials, GLP-1 receptor agonists showed no increase in cancer risk compared to placebo or other diabetes drugs (p=0.46).
What the researchers found
A meta-analysis of 34 randomized controlled trials involving 50,452 patients with type 2 diabetes found no increased risk of cancer with GLP-1 receptor agonist use. The overall odds ratio was 1.04 (95% CI 0.94–1.15, p=0.46), meaning cancer rates were essentially the same between GLP-1 users and controls.
Breaking it down by drug: liraglutide (OR 1.08, p=0.38), exenatide (OR 1.00, p=1.00), semaglutide (OR 0.89, p=0.80), and albiglutide (OR 1.07, p=0.93) all showed no increased risk. A subanalysis of trials lasting more than 3 years also found no signal (OR 1.03, p=0.60).
Statistical heterogeneity was low across all comparisons, strengthening confidence in the finding.
Why it matters
Animal studies had raised concerns about GLP-1 drugs potentially causing thyroid tumors, leading to persistent worry about cancer risk. This large meta-analysis of human trial data provides strong reassurance: across more than 50,000 patients and multiple drugs, there was no evidence of increased cancer risk. This is critical safety information for the millions of people now taking these medications for diabetes and weight loss.
The numbers in context
N=50,452 · 34 RCTs · OR 1.04 (95% CI 0.94–1.15) overall · p=0.46 · Low heterogeneity · >3-year subanalysis: OR 1.03
How the study worked
Systematic review and meta-analysis of randomized controlled trials (≥24 weeks duration) from MEDLINE, Embase, and Cochrane databases through October 2018. Included trials comparing GLP-1 receptor agonists to placebo or other diabetes drugs in type 2 diabetes patients, with cancer incidence as an outcome. Fixed effects model used to calculate odds ratios. Subanalyses by individual drug and by trial duration (>3 years).
Who was studied
50,452 adults with type 2 diabetes from 34 randomized controlled trials
What this study cannot tell us
Cancer typically develops over many years, and even the 3+ year trials may be too short to detect a true long-term signal. The analysis focused on type 2 diabetes patients and may not apply to the obesity population now using these drugs. Individual cancer types were not analyzed separately. Published through 2018, so newer data from large cardiovascular outcome trials may not be fully captured.
How to read the evidence
This is a meta-analysis of randomized controlled trials — the highest level of evidence. The large sample size, low heterogeneity, and consistent results across individual drugs and time periods strengthen the conclusion. Rated high evidence.
When this study was published
Published in 2019 with data through October 2018. While newer and larger trials have since reported, this meta-analysis captures the core safety evidence from the formative GLP-1 clinical trial program. Subsequent data have continued to show no cancer signal.
The bigger picture
The cancer question has followed GLP-1 drugs since their approval, partly because rodent studies showed thyroid C-cell tumors with liraglutide and semaglutide. This meta-analysis adds to the growing body of human evidence that this rodent finding doesn't translate to people. As GLP-1 drugs are prescribed to tens of millions for both diabetes and obesity, ongoing post-marketing surveillance remains important, but this analysis should reassure patients and prescribers about medium-term safety.
Questions still open
- Will 10+ year follow-up data confirm that GLP-1 drugs remain cancer-neutral over very long-term use?
- Does the cancer safety profile differ in the obesity population versus the diabetes population studied here?
- Should thyroid cancer specifically be analyzed separately given the rodent C-cell tumor signal?
Common questions
Why were people worried about GLP-1 drugs and cancer?
Is this enough data to be sure GLP-1 drugs don't cause cancer?
Read the original research
Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
Journal of diabetes research, 2019, 1534365
Citation
Liu, Yufang; Zhang, Xiaomei; Chai, Sanbao; Zhao, Xin; Ji, Linong. (2019). Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.. Journal of diabetes research, 2019, 1534365. https://doi.org/10.1155/2019/1534365